Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to news from the U.S. Food and ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Moderna Inc. closed $131.08 below its 52-week high ($170.47), which the company achieved on May 24th.

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

To understand how Summit Therapeutics ( SMMT 8.36%) could turn an investment of $1,000 into $5,000 by 2030, we need to first ...

Most years, I find one or two stocks among the biggest losers that I think are worth buying. This year there are three — ...

Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years ...